Feeds:
Posts
Comments

Archive for the ‘Pfizer’ Category

*****

TODAY’S NEWS:

Cheap drug could be a life-saver – A cheap drug that can stop bleeding in recently injured accident patients could potentially save the lives of tens of thousands worldwide, a new study says. Researchers studied the effects of tranexamic acid, or TXA, in more than 10,000 adult trauma patients in 40 countries who received the drug within 8 hours of being injured. They compared those patients’ outcomes to more than 10,000 accident victims who got a placebo treatment. The study was published online Tuesday in the medical journal Lancetmore

Pfizer ends development of one experimental RA drug from Trubion; keeps another one going.

Glaxo gets FDA OK for combo prostate treatment.

Human Genome Sciences: low expectations for Hepatitis C drug approval.

Judge to Abbott: Pay reps overtime.

RECOMMENDED

Social Media 101/201. Here at Impactiviti, we’re immersed in both social media and pharma. We’re happy to provide on-site workshops for our clients who need to bring sales/marketing/training/executive teams up to speed on Trends in Social Media.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for details.

PLUS

Fresh updates to the astonishingly helpful Dose of Digital Social Media (Pharma/Healthcare) Wiki. And, a little thought-provoking tidbit: The Red Pill or the Blue Pill?

JUST FOR FUN

Nature’s Patterns in Photography. Sheer eye candy.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

Impactiviti has launched a new venture, and we’d like to ask for your help to make it a success! Introducing the Impactiviti Talent Network – on-line job search joined to social networking. This can help you as a job seeker, AND as a company posting openings!

TODAY’S NEWS:

Head of Pfizer R&D pulls up stakes, goes to AstraZeneca.

Pfizer‘s Inspra meets primary study goals early – Pfizer reported Thursday that it plans to stop enrolling patients ahead of schedule in a late-stage trial of Inspra (eplerenone) after those taking the drug experienced a significant reduction in risk of cardiovascular death or heart failure hospitalisation compared with those receiving placebo...more

Sanofi‘s prostate cancer drug: 28% survival improvement in study – Sanofi-Aventis’ cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment, the outcome of a final-stage trial showed. The French drugmaker said on Thursday that the combination of the treatments led to an improved median overall survival of 15.1 months against 12.7 months in patients who took a chemotherapy of mitoxantrone with prednisone/prednisolonemore

Intermune to lay off 40% of workforce – InterMune Inc. said it will fire about 60 employees, or 40 percent of its workforce, to reduce costs after the U.S. Food and Drug Administration rejected the company’s lung drug earlier this month...more

RECOMMENDED

Facebook page development/monitoring. If your marketing group is thinking about Facebook as a platform, we have the development and management partners you need for social media.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

I don’t usually wander into political waters on this blog. But I found this article to be so compelling and cogent, I had to share. America’s New Culture War: Free Enterprise vs. Government Control. Worth the read!

JUST FOR FUN

Splash of yellow. From my backyard. And, daisies in the evening.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****
TODAY’S NEWS

Novartis: huge punitive fine in discrimination case. $250 million game-changing dollars.

FDA to the public – let’s talk more. Or, tell us more about what we should tell you.

GSK and more Avandia flak. This story will never end, it seems.

Pfizer and multiple corporate cultures. An interesting interview at Forbes magazine.

The Manual of Clinical Psychopharmacology gives a raspberry to the Vanda/Novartis schizophrenia drug Fanapt.

RECOMMENDED

Software training. The Impactiviti partner network has the providers you need for training on software systems. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Good advice for all situations, including business: Give them your heart, then your head. From my friend Drew McLellan.

JUST FOR FUN

Visual treat. The stunning colors of Glacier National Park. I visited there once, years ago – it really is magnificent! And – Slow Motion Gum And Gelatin. Cooler than you might think (quick video).

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****
TODAY’S NEWS

Sanofi taking a heavy dice-roll on Multaq: 11,000-patient trial on expanded use.

A glimpse into Merck‘s late-stage pipeline. Very diverse group of molecules and conditions. Here’s an interesting little extra on the cholesterol drug.

FDA launches 1-800-TATTLE: The FDA is asking healthcare professionals to keep an eye out for violative promotion and to call 1-877-RX-DDMAC or emailing badad@fda.com when they see itmore

Pfizer: NYC layoffs and relos, plus selling a midtown building. And, late-breaking, Takeda also embarking on major cuts.

The VA about to tighten the rules on drug sales rep interactions. Part of a nationwide trend.

RECOMMENDED

Management Training. The Impactiviti network can help you with all your needs for training managers, finding the optimal suppliers for you. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

So…who’s been doing the best Social Media in Pharma? The new Dosie Award winners were announced live at the BDI Social Communications in Healthcare event yesterday.

JUST FOR FUN

Sunsets. Nice.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS

Little Pricey Pill: A BusinessWeek slam on the Nexium approach to me-too drug marketing.

Pfizer and the Neurontin marketing fraud: $142M please.

Head-to-head MS drug effectiveness studies coming. This should be interesting.

RECOMMENDED

Video storytelling – Impactiviti’s vendor/partners have just what you need for directing and producing corporate videos.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

The latest Impactiviti Connection e-newsletter is up! You can subscribe here.

PLUS

But Are We Communicating? My rant on pharma communications, regulations, and social media.

JUST FOR FUN

Top 100 April Fools Pranks. ‘Cause it’s about that time…

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS

AstraZeneca still waiting for the upside of MedImmune acquisition.

Pfizer: More Lipitor, fewer heart complications – A reanalysis of research data found a high dose of popular cholesterol pill Lipitor lowers risk of heart attack and stroke in some patients with both heart disease and kidney disease, the drug’s maker said Mondaymore

Fred Hassan heads to Bausch & Lomb.

Novartis‘ Tekturna post-heart attack: Not a good idea. “Given these results, we are not currently recommending the use of this agent in addition to other inhibitors of the renin-angiotensin system in this specific patient population.”

Access to docs flat, but appointments on the rise.

RECOMMENDED

eLearning Development – From modules to virtual preceptorships to virtual worlds, we’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

“I hate her uterus!” DTC, infertility, and a very effective on-line campaign. IncreaseYourChances.

JUST FOR FUN

Human, squirrel, or anvil? A great Dilbert cartoon today!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

As more and more pharmaceutical companies dip their toes into social media, one of the issues that surfaces regularly is this: do you put someONE in charge of a blog and/or Twitter account, or do you make it more anonymous? Or something else?

Let’s discuss this. I’ll put out my thoughts; add yours in the comments.

I’ve always advocated that pharma companies should use social networks to humanize their companies, which means employing human faces and voices – having real, authentic, and effective communicators working these channels. People. Folks you can relate to meet, meet at a conference, carry on backchannel discussions with, etc.

J&J has been very effective with this; Marc Monseau has served effectively as the “voice” of J&J in the socialsphere. Recently, Pfizer (@pfizer_news on Twitter) has updated its Twitter account to include a face and a name – Jennifer Kokell, self-identified as tweeting from Global Corporate Media Relations in NYC. Jennifer works with Ray Kerins, who has been aggressively shaking up the Communications practices at Pfizer, including a healthy push into social media.

But the question comes up – what if a company’s social media presence is too dependent on one person? And here the fine line must be walked – on the one hand, social media is all about individuals and personality and dialogue between people – but companies are not one person. And people move on.

By and large, people don’t want another nameless, faceless monolithic channel in social media – some unnamed drone churning out one-way communications in the name of “the company” who has about as much relational value as a dead fish. So – how to strike the balance?

Here’s one idea for larger companies – have a team presence for your blog and Twitter account. Multiple people – say, 3 or 4 – who contribute posts and tweets about a cross-section of the company’s activities. These would be real people with names, pictures, and off-line appearances – but the team approach would reflect the reality that a company IS made up of diverse individuals, and would also make the social media presence less dependent on a solo individual (reflecting the hit-by-a-bus reality of the non-expendable individual). While J&J’s social presence is spearheaded by Marc Monseau, their corporate blog actually has other contributing authors.

That would be one approach for an “official” social media presence. What about “unofficial” social media representatives? I like what is happening at Novartis, where various individuals such as Brad Pendergraph, Colin Foster, Mark Davis, Erik Hawkinson, Ben Atkins and others tweet as professional and accessible human beings who work at Novartis (thus achieving some humanizing of the company) but who have a unique presence reflecting their personal interests and professional perspectives. In fact, with Novartis, the “unofficial” social media presence has far outstripped progress on its “official” corporate social media footprint.

We’re all still on the learning curve with this stuff and companies are experimenting and evolving. What’s your take? One? Many? None? How can a company project humanity and authenticity without too much solo-representative risk?

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Download free e-book: Getting Started with Social Networking.

Read Full Post »

Older Posts »

Follow

Get every new post delivered to your Inbox.

Join 27 other followers